Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome

By  

Current Pharmaceutical Design, Vol. 20, Iss. 31, 2014-01 ,pp. : 5025-5038

Bentham Science Publishers

Access to resources Recommend Favorite

The Association of Dysglycaemia and Cardiovascular Disease in Patients with Metabolic Syndrome

By Gong W   Yang Z   Ye W   Du Y   Lu B   Wang M   Li Q   Zhang W   Pan Y   Feng X   Zhou W   Zhang Y   Wen J   Yang Z   Yang Y   Zhu X   Hu R  

The Journal of International Medical Research, Vol. 37, Iss. 5, 2009-09 ,pp. : 1486-1492

Field House Publishing

Access to resources Recommend Favorite

Molecular Targets of Diabetic Cardiovascular Complications

By  

Current Drug Targets, Vol. 6, Iss. 4, 2005-06 ,pp. : 487-494

Bentham Science Publishers

Access to resources Recommend Favorite

TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome

By  

Current Pharmaceutical Design, Vol. 24, Iss. 17, 2018-05 ,pp. : 1905-1911

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of PPAR&bgr;/δ in the Management of Metabolic Syndrome and its Associated Cardiovascular Complications

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 11, Iss. 4, 2011-12 ,pp. : 273-284

Bentham Science Publishers

Access to resources Recommend Favorite